Literature DB >> 25107638

Canavan disease - unusual imaging features in a child with mild clinical presentation.

Ho V Nguyen1, Gisele E Ishak.   

Abstract

Canavan disease is a rare hereditary leukodystrophy that manifests in early childhood. Associated with rapidly progressive clinical deterioration, it usually results in death by the third year of life. The predominant MRI appearance is diffuse and symmetrical white matter disease. We discuss an atypical, late presentation of Canavan disease with a benign clinical course and uncharacteristic imaging features. This case introduces a previously unreported pattern of diffuse cortical abnormality without significant white matter involvement.

Entities:  

Mesh:

Year:  2014        PMID: 25107638     DOI: 10.1007/s00247-014-3116-8

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  6 in total

1.  Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay.

Authors:  Annette Feigenbaum; Robert Moore; Joe Clarke; Stacy Hewson; David Chitayat; Peter N Ray; Tracy L Stockley
Journal:  Am J Med Genet A       Date:  2004-01-15       Impact factor: 2.802

2.  Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.

Authors:  Christopher G Janson; Edwin H Kolodny; Bai-Jin Zeng; Srinivasa Raghavan; Gregory Pastores; Paola Torres; Mitra Assadi; Scott McPhee; Olga Goldfarb; Beth Saslow; Andrew Freese; D J Wang; Larissa Bilaniuk; David Shera; Paola Leone
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

3.  Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.

Authors:  M Velinov; N Zellers; J Styles; K Wisniewski
Journal:  Clin Genet       Date:  2007-12-06       Impact factor: 4.438

4.  Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.

Authors:  Raji Mathew; Peethambaran Arun; Chikkathur N Madhavarao; John R Moffett; M A Aryan Namboodiri
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

5.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

6.  Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.

Authors:  M H Baslow; D N Guilfoyle
Journal:  Biochimie       Date:  2012-11-11       Impact factor: 4.079

  6 in total
  3 in total

1.  Atypical clinical and radiological course of a patient with Canavan disease.

Authors:  Catherine Sarret; Odile Boespflug-Tanguy; Diana Rodriguez
Journal:  Metab Brain Dis       Date:  2015-11-19       Impact factor: 3.584

2.  Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.

Authors:  Marisa I Mendes; Desirée Ec Smith; Ana Pop; Pascal Lennertz; Matilde R Fernandez Ojeda; Warsha A Kanhai; Silvy Jm van Dooren; Yair Anikster; Ivo Barić; Caroline Boelen; Jaime Campistol; Lonneke de Boer; Ariana Kariminejad; Hulya Kayserili; Agathe Roubertie; Krijn T Verbruggen; Christine Vianey-Saban; Monique Williams; Gajja S Salomons
Journal:  Hum Mutat       Date:  2017-02-14       Impact factor: 4.878

3.  Neurometabolic Diagnosis in Children who referred as Neurodevelopmental Delay (A Practical Criteria, in Iranian Pediatric Patients).

Authors:  Parvaneh Karimzadeh; Narjes Jafari; Habibeh Nejad Biglari; Sayena Jabbehdari; Simin Khayat Zadeh; Farzad Ahmad Abadi; Azra Lotfi
Journal:  Iran J Child Neurol       Date:  2016
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.